PMID- 25876102
OWN - NLM
STAT- MEDLINE
DCOM- 20160420
LR  - 20181113
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Print)
IS  - 0891-3668 (Linking)
VI  - 34
IP  - 5
DP  - 2015 May
TI  - Immunogenicity and safety of meningococcal C conjugate vaccine in children and 
      adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.
PG  - e113-8
LID - 10.1097/INF.0000000000000630 [doi]
AB  - BACKGROUND: We aimed to evaluate the Meningococcal (Neisseria meningitidis) C 
      conjugated (MCC) vaccine seroconversion and adverse events (AEs) in HIV-infected 
      and HIV-uninfected children and adolescents in Rio de Janeiro, Brazil. METHODS: 
      HIV-infected or HIV-uninfected subjects, 2-18 years old, with CD4+ T-lymphocyte 
      cell (CD4) percentage >15%, without active infection or antibiotic use, were 
      enrolled. All patients were evaluated before and 1-2 months after immunization 
      for seroconversion (defined as >/=4-fold titer increase in human serum bactericidal 
      activity) and at 20 minutes, 3 and 7 days after immunization for AEs. Factors 
      associated with seroconversion among HIV-infected group were studied. RESULTS: 
      Two hundred four subjects were enrolled: 154 HIV-infected and 50 HIV-uninfected. 
      Median age was 12 years, and 53% were female. Among the HIV-infected group, 82 
      (53%) had a history of at least 1 C clinical category of Centers for Diseases 
      Control and Prevention event, and 134 (87%) were using combination antiretroviral 
      therapy. The median nadir CD4 percentage was 13% (0-47%). Seventy-six (37.3%) 
      experienced mild AEs. Seroconversion occurred in 46 of 154 (30%) in the 
      HIV-infected group and in 38 of 50 (76%) in the uninfected group (P < 0.01). 
      Factors associated with seroconversion in the HIV-infected group were as follows: 
      never had a C clinical category event [odds ratio (OR) = 2.1, 95% confidence 
      interval (CI): 1.0-4.4]; undetectable viral load at immunization (OR: 2.4, 95% 
      CI: 1.1-5.2) and higher CD4 nadir/100 cells (OR: 1.1, 95% CI: 1.0-1.2). 
      CONCLUSION: MCC vaccine should be administered to HIV-infected children and 
      adolescents after maximum immunologic and virologic benefits have been achieved 
      with combination antiretroviral therapy. Our data suggest that a single dose of 
      MCC vaccine is insufficient for HIV-infected individuals 2-18 years of age.
FAU - Frota, Ana Cristina C
AU  - Frota AC
AD  - From the *Department of Pediatrics and daggerDepartment of Preventive Medicine, 
      Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; double daggerDepartment of 
      Microbiology and Immunology, Universidade do Estado do Rio de Janeiro, Rio de 
      Janeiro, Brazil; and  section signInfectious Diseases Epidemiology Research Unit, University 
      of Pittsburgh, Pittsburgh, PA.
FAU - Milagres, Lucimar G
AU  - Milagres LG
FAU - Harrison, Lee H
AU  - Harrison LH
FAU - Ferreira, Bianca
AU  - Ferreira B
FAU - Menna Barreto, Daniela
AU  - Menna Barreto D
FAU - Pereira, Gisele S
AU  - Pereira GS
FAU - Cruz, Aline C
AU  - Cruz AC
FAU - Pereira-Manfro, Wania
AU  - Pereira-Manfro W
FAU - de Oliveira, Ricardo Hugo
AU  - de Oliveira RH
FAU - Abreu, Thalita F
AU  - Abreu TF
FAU - Hofer, Cristina B
AU  - Hofer CB
LA  - eng
GR  - D43 TW006592/TW/FIC NIH HHS/United States
GR  - R01 TW008397/TW/FIC NIH HHS/United States
GR  - 5R01 TW008397/TW/FIC NIH HHS/United States
GR  - D43TW006592/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Meningococcal Vaccines)
RN  - 0 (serogroup C meningococcal conjugate vaccine)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Bacterial/blood
MH  - Brazil/epidemiology
MH  - Child
MH  - Female
MH  - HIV Infections/epidemiology/*immunology
MH  - Humans
MH  - Male
MH  - Meningococcal Infections/*prevention & control
MH  - Meningococcal Vaccines/*adverse effects/*immunology
MH  - Prospective Studies
PMC - PMC4454630
MID - NIHMS644203
COIS- Conflict of interest: For the remaining authors there was no conflicts of 
      interest.
EDAT- 2015/04/16 06:00
MHDA- 2016/04/21 06:00
PMCR- 2016/05/24
CRDT- 2015/04/16 06:00
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/04/21 06:00 [medline]
PHST- 2016/05/24 00:00 [pmc-release]
AID - 00006454-201505000-00011 [pii]
AID - 10.1097/INF.0000000000000630 [doi]
PST - ppublish
SO  - Pediatr Infect Dis J. 2015 May;34(5):e113-8. doi: 10.1097/INF.0000000000000630.